THERA65
About
Resistance to cancer therapies is the primary cause of limited therapeutic benefit for oncology patients. Current treatment strategies, whether generalized chemotherapy or targeted therapies, often fail due to the development of resistance.
THERA65 is an innovative biotech startup focused on developing personalized diagnostics and therapies for oncology patients. Our technology is based on the groundbreaking discovery of the new biomarker p65BTK, an oncogenic protein expressed in various solid cancer.
Market Target
B2B
Main Sector of Activity (SINGLE CHOICE)
Biotechnology
Field of aplication (Multiple choice)
Pharmaceutics
Representatives
Remote
Remote
CEO
THERA65